Profile data is unavailable for this security.
About the company
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
- Revenue in USD (TTM)0.00
- Net income in USD-94.05m
- Incorporated2015
- Employees24.00
- LocationOutlook Therapeutics Inc111 S. Wood Avenue, Unit #100ISELIN 08830United StatesUSA
- Phone+1 (609) 619-3990
- Websitehttps://outlooktherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TriSalus Life Sciences Inc | 24.74m | -57.21m | 131.32m | 112.00 | -- | -- | -- | 5.31 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Fractyl Health Inc | 119.00k | -65.88m | 133.72m | 102.00 | -- | 1.89 | -- | 1,123.67 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
aTyr Pharma Inc | 588.00k | -57.90m | 137.95m | 56.00 | -- | 1.69 | -- | 234.61 | -0.9047 | -0.9047 | 0.0092 | 1.08 | 0.0049 | -- | 0.4034 | 10,500.00 | -48.51 | -45.45 | -53.89 | -52.74 | -- | -- | -9,846.26 | -784.19 | -- | -- | 0.0202 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
Kodiak Sciences Inc | 0.00 | -197.68m | 138.90m | 111.00 | -- | 0.6476 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
CervoMed Inc | 9.65m | -5.04m | 138.99m | 8.00 | -- | 2.78 | -- | 14.40 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
Quantum-Si Inc | 1.70m | -89.35m | 139.06m | 159.00 | -- | 0.596 | -- | 81.70 | -0.6302 | -0.6302 | 0.012 | 1.64 | 0.0057 | 0.2321 | 3.68 | 10,704.40 | -29.89 | -- | -30.99 | -- | 53.41 | -- | -5,249.65 | -- | 20.13 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
Actuate Therapeutics Inc | 0.00 | -27.77m | 139.71m | 6.00 | -- | -- | -- | -- | -1.45 | -1.45 | 0.00 | -0.7114 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -134.25 | -- | -- | -- | -- | -22.74 | -- | -- | -- |
Prelude Therapeutics Inc | 0.00 | -129.85m | 140.31m | 128.00 | -- | 0.5898 | -- | -- | -1.80 | -1.80 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -51.44 | -47.21 | -55.69 | -51.07 | -- | -- | -- | -- | -- | -- | 0.0028 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
ProQR Therapeutics NV | 20.88m | -24.05m | 141.31m | 157.00 | -- | 3.97 | -- | 6.77 | -0.2956 | -0.2956 | 0.2566 | 0.4353 | 0.1406 | -- | -- | 132,990.80 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
Outlook Therapeutics Inc | 0.00 | -94.05m | 141.93m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
Invivyd Inc | 2.26m | -203.84m | 143.33m | 94.00 | -- | 1.02 | -- | 63.31 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Fennec Pharmaceuticals Inc | 48.89m | 2.74m | 143.37m | 36.00 | 134.70 | -- | 52.42 | 2.93 | 0.0389 | 0.0389 | 1.75 | -0.0497 | 1.18 | 1.21 | 6.63 | -- | 6.62 | -73.43 | 7.70 | -84.32 | 95.55 | -- | 5.59 | -383.28 | 7.75 | 1.87 | 1.05 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
Century Therapeutics Inc | 2.04m | -131.39m | 144.02m | 152.00 | -- | 0.6472 | -- | 70.53 | -2.04 | -2.04 | 0.031 | 2.63 | 0.0049 | -- | -- | 13,434.21 | -31.52 | -- | -33.04 | -- | -- | -- | -6,434.23 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
Repare Therapeutics Inc | 68.68m | -68.52m | 149.41m | 179.00 | -- | 0.7336 | -- | 2.18 | -1.63 | -1.63 | 1.61 | 4.80 | 0.2558 | -- | 6.34 | 383,703.90 | -25.52 | -23.40 | -30.30 | -26.37 | -- | -- | -99.76 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Acumen Pharmaceuticals Inc | 0.00 | -64.86m | 150.20m | 51.00 | -- | 0.6157 | -- | -- | -1.11 | -1.11 | 0.00 | 4.06 | 0.00 | -- | -- | 0.00 | -27.82 | -- | -29.32 | -- | -- | -- | -- | -- | -- | -- | 0.1075 | -- | -- | -- | -22.20 | -- | -- | -- |
P3 Health Partners Inc | 1.40bn | -69.48m | 153.82m | 400.00 | -- | 0.4169 | -- | 0.1097 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Holder | Shares | % Held |
---|---|---|
Great Point Partners LLCas of 30 Jun 2024 | 1.70m | 7.19% |
Tang Capital Management LLCas of 30 Jun 2024 | 1.62m | 6.85% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 623.25k | 2.64% |
Sphera Funds Management Ltd.as of 30 Jun 2024 | 571.43k | 2.42% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 536.05k | 2.27% |
Altium Capital Management LPas of 30 Jun 2024 | 501.79k | 2.12% |
Caligan Partners LPas of 30 Jun 2024 | 500.00k | 2.11% |
Rosalind Advisors, Inc.as of 30 Jun 2024 | 450.00k | 1.90% |
Schonfeld Strategic Advisors LLCas of 30 Jun 2024 | 285.71k | 1.21% |
Boothbay Fund Management LLCas of 30 Jun 2024 | 250.00k | 1.06% |